NASDAQ:ADRO - Aduro Biotech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.75
  • Forecasted Upside:
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Aduro Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADRO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$3.75
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aduro Biotech in the last 3 months. The average price target is $3.75, with a high forecast of $3.75 and a low forecast of $3.75. The average price target represents a ∞ upside from the last price of $0.00.
Buy
The current consensus among 2 investment analysts is to buy stock in Aduro Biotech. This rating has held steady since November 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2020HC WainwrightReiterated RatingBuy$3.75High
i
6/5/2020OppenheimerInitiated CoverageHoldHigh
i
Rating by Justin Kim at Oppenheimer Holdings Inc.
6/2/2020HC WainwrightBoost Price TargetBuy$3.75 ➝ $4.00Low
i
5/4/2020OppenheimerReiterated RatingHoldHigh
i
1/31/2020SVB LeerinkBoost Price TargetOutperform$3.00 ➝ $7.00High
i
1/9/2020CowenDowngradeOutperform ➝ Market PerformHigh
i
Rating by Chris Shibutani at Cowen Inc
12/18/2019HC WainwrightLower Price TargetBuy$7.00 ➝ $4.00High
i
12/18/2019William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by M. Phipps at William Blair
8/2/2019CowenReiterated RatingBuyHigh
i
6/3/2019CIBCReiterated RatingOutperform ➝ Market PerformHigh
i
6/3/2019OppenheimerDowngradeOutperform ➝ Market PerformHigh
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/8/2019CowenReiterated RatingBuyHigh
i
4/15/2019SVB LeerinkReiterated RatingOutperform ➝ Outperform$9.00High
i
Rating by D. Graybosch at SVB Leerink LLC
3/19/2019OppenheimerReiterated RatingBuyLow
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/19/2018HC WainwrightReiterated RatingBuy$8.30High
i
Rating by Joseph Pantginis at HC Wainwright
11/13/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$30.00 ➝ $10.00High
i
11/12/2018OppenheimerSet Price TargetBuy$10.00Low
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/12/2018HC WainwrightSet Price TargetBuy$8.00Low
i
Rating by Joseph Pantginis at HC Wainwright
10/31/2018CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
10/30/2018OppenheimerSet Price TargetBuy$10.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
10/3/2018William BlairReiterated RatingBuyLow
i
Rating by Matt Phipps at William Blair
10/2/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/2/2018Canaccord GenuityReiterated RatingBuy$30.00High
i
8/2/2018Bank of AmericaLower Price TargetUnderperform ➝ Underperform$8.00 ➝ $6.00High
i
8/2/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Joseph Pantginis at HC Wainwright
5/3/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Joseph Pantginis at HC Wainwright
4/26/2018HC WainwrightSet Price TargetBuy$10.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
3/5/2018Cantor FitzgeraldReiterated RatingBuy$15.00Low
i
Rating by M. Goldstein at Cantor Fitzgerald
3/2/2018Bank of AmericaLower Price TargetUnderperform ➝ Underperform$9.00 ➝ $8.00Low
i
3/2/2018Canaccord GenuityReiterated RatingBuyLow
i
Rating by John Newman at Canaccord Genuity
3/2/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Joseph Pantginis at HC Wainwright
2/21/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$15.00High
i
Rating by M. Goldstein at Cantor Fitzgerald
1/16/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/19/2017HC WainwrightSet Price TargetBuy$10.00Low
i
Rating by Joseph Pantginis at HC Wainwright
12/14/2017Canaccord GenuitySet Price TargetBuy$30.00Medium
i
Rating by John Newman at Canaccord Genuity
12/13/2017OppenheimerLower Price TargetOutperform$15.00 ➝ $13.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/13/2017HC WainwrightLower Price TargetBuy ➝ Buy$18.00 ➝ $9.50Low
i
Rating by Joseph Pantginis at HC Wainwright
12/11/2017OppenheimerSet Price TargetBuy$15.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/1/2017HC WainwrightSet Price TargetBuy$18.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
10/30/2017OppenheimerInitiated CoverageBuy$15.00N/A
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
10/17/2017HC WainwrightSet Price TargetBuy$18.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
10/2/2017William BlairReiterated RatingOutperformHigh
i
9/27/2017HC WainwrightReiterated RatingBuy$18.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
8/3/2017Canaccord GenuitySet Price TargetBuy$30.00Low
i
Rating by John Newman at Canaccord Genuity
8/3/2017HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Joseph Pantginis at HC Wainwright
7/18/2017CowenInitiated CoverageOutperformLow
i
5/3/2017Canaccord GenuityReiterated RatingBuy$30.00Medium
i
Rating by John Newman at Canaccord Genuity
5/1/2017HC WainwrightInitiated CoverageBuy$18.00Low
i
Rating by Joseph Pantginis at HC Wainwright
5/1/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$18.00Low
i
3/27/2017Canaccord GenuitySet Price TargetBuy$30.00Low
i
Rating by John Newman at Canaccord Genuity
3/7/2017(FBRC)Reiterated RatingBuy$23.00N/A
i
Rating by Christopher James at (FBRC)
3/7/2017Roth CapitalReiterated RatingBuy$17.00N/A
i
Rating by M. Breidenbach at Roth Capital
3/2/2017Canaccord GenuitySet Price TargetBuy$30.00N/A
i
Rating by John Newman at Canaccord Genuity
1/19/2017Canaccord GenuitySet Price TargetBuy$30.00N/A
i
Rating by John Newman at Canaccord Genuity
12/6/2016Canaccord GenuitySet Price TargetBuy$30.00N/A
i
Rating by John Newman at Canaccord Genuity
11/25/2016Roth CapitalReiterated RatingBuy$20.00N/A
i
11/22/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Christopher James at (FBRC)
11/21/2016Canaccord GenuitySet Price TargetBuy$30.00N/A
i
Rating by John Newman at Canaccord Genuity
11/14/2016(FBRC)Reiterated RatingOutperform$20.00N/A
i
Rating by Christopher James at (FBRC)
10/27/2016Roth CapitalReiterated RatingBuy$22.00 ➝ $20.00N/A
i
Rating by Joseph Pantginis at Roth Capital
10/26/2016(FBRC)Reiterated RatingOutperform$22.00 ➝ $20.00N/A
i
Rating by Christopher James at (FBRC)
10/24/2016Canaccord GenuitySet Price TargetBuy$30.00N/A
i
Rating by John Newman at Canaccord Genuity
10/24/2016SVB LeerinkSet Price TargetBuy$14.00N/A
i
8/5/2016Canaccord GenuityReiterated RatingBuy$30.00N/A
i
Rating by John Newman at Canaccord Genuity
7/11/2016Roth CapitalReiterated RatingBuy$22.00N/A
i
Rating by Joseph Pantginis at Roth Capital
6/6/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Christopher James at (FBRC)
5/17/2016SVB LeerinkReiterated RatingOutperform$48.00 ➝ $14.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
5/17/2016(FBRC)Lower Price TargetOutperform$30.00 ➝ $22.00N/A
i
Rating by Christopher James at (FBRC)
5/16/2016Roth CapitalReiterated RatingBuy$46.00 ➝ $22.00N/A
i
Rating by Joseph Pantginis at Roth Capital
5/16/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
5/14/2016(FBRC)Reiterated RatingBuy$30.00 ➝ $34.00N/A
i
Rating by Christopher James at (FBRC)
5/5/2016SVB LeerinkReiterated RatingBuy$48.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
5/3/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
4/29/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Christopher James at (FBRC)
(Data available from 4/21/2016 forward)
Aduro Biotech logo
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $10.93
$2.28
$14.60

52 Week Range

Now: N/A

Volume

171,500 shs

Average Volume

162,237 shs

Market Capitalization

$236.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Aduro Biotech?

The following Wall Street sell-side analysts have issued stock ratings on Aduro Biotech in the last twelve months: HC Wainwright, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for ADRO.

What is the current price target for Aduro Biotech?

1 Wall Street analysts have set twelve-month price targets for Aduro Biotech in the last year. Their average twelve-month price target is $3.75. HC Wainwright has the highest price target set, predicting ADRO will reach $3.75 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.75 for Aduro Biotech in the next year.
View the latest price targets for ADRO.

What is the current consensus analyst rating for Aduro Biotech?

Aduro Biotech currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADRO will outperform the market and that investors should add to their positions of Aduro Biotech.
View the latest ratings for ADRO.

What other companies compete with Aduro Biotech?

How do I contact Aduro Biotech's investor relations team?

Aduro Biotech's physical mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company's listed phone number is (206) 485-7051 and its investor relations email address is [email protected] The official website for Aduro Biotech is www.aduro.com.